Clinical Trial

Vitiligo, New Treatment and Serum s100B

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated January 10, 2025 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors
Trial Details
NCT Number NCT06768840
Lead Sponsor South Valley University
Conditions Vitiligo, Generalized
Enrollment 50 participants
Start Date 2024-10-02
Primary Completion 2025-08 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-01-10